New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
10:46 EDTMAC, PTR, TTM, STT, ALKSHigh option volume stocks: ALKS TTM MAC STT PTR
News For ALKS;TTM;MAC;STT;PTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
11:33 EDTALKSAlkermes label for Aristada better than expected, says Morgan Stanley
Subscribe for More Information
08:02 EDTALKSAlkermes approval brings 'key' near-term growth driver, says Leerink
Subscribe for More Information
07:31 EDTSTTbloomberg to hold a summit
Subscribe for More Information
07:02 EDTALKSAlkermes approval an incremental positive, says JPMorgan
Subscribe for More Information
06:44 EDTALKSAlkermes approval removes 'important overhang,' says Credit Suisse
Subscribe for More Information
October 5, 2015
18:24 EDTALKSAlkermes announces FDA approval of ARISTADA
Alkermes announced that the U.S. FDA has approved ARISTADA extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. Alkermes is preparing to launch ARISTADA immediately.
October 1, 2015
08:21 EDTMACMacerich to hold a conference call
Subscribe for More Information
September 30, 2015
17:48 EDTMACMacerich forms joint ventures on assets valued at $5.4B
Macerich has reached agreement to form joint ventures to which Macerich will contribute interests in eight assets with expected cash proceeds to Macerich totaling $2.3B. GIC will have a 40% interest in five assets and Heitman will have a 49% interest in three assets. The transactions are expected to close in phases starting in October 2015 and concluding in 1Q16. Concurrent with or prior to the joint venture closings, the company is planning to put financing on South Plains Mall and Twenty Ninth Street center and will refinance the debt on Washington Square, Los Cerritos Center and Arrowhead Towne Center. Included in the total cash proceeds, mentioned above, is Macerich's share of the excess financing proceeds which is estimated to be $1.14B. Use of the proceeds is expected to include share repurchases under the company's announced $1.2B share repurchase program, a pay down of the line of credit debt balance and for a special dividend of $3.50-$4.50 per share.
17:31 EDTMACMacerich authorizes $1.2B share repurchase program
Subscribe for More Information
08:23 EDTSTTAtlanta Society of Finance & Investmen Professionals to hold a meeting
Subscribe for More Information
September 28, 2015
06:57 EDTTTMNHTSA mulls Takata air bag recall expansion, Bloomberg reports
The National Highway Traffic Safety Administration, or NHTSA, is mulling an order that would expand that recalls of Takata (TKTDY) air bags and has contacted seven manufacturers who may be affected, including Volkswagen (VLKAY) and Tesla (TSLA), Bloomberg reports. Takata had identified seven companies that it has supplied with air bag inflators that use ammonium nitrate propellant, the report says, citing NHTSA letters dated September 22. The NHTSA also contacted Mercedes-Benz (DDAIF), Jaguar Land Rover (TTM), Suzuki (SZKMF), Volvo Trucks (VOLVY), and Spartan Motors (SPAR), the report says. Reference Link
September 24, 2015
09:58 EDTSTTState Street selected by Department of Finance Canada as collateral manager
State Street announced that it has been selected by the Department of Finance Canada to act as collateral manager and custodian for the Government of Canada's currency swap program.
September 23, 2015
10:10 EDTMACHigh option volume stocks
High option volume stocks: MAC NYCB USL NCLH TRN ZOES
September 22, 2015
08:00 EDTALKSJefferies sees buying opportunities in select biotech names
Analysts at Jefferies say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). The Jefferies Biotechnology research team is led by Brian Abrahams, Eun Yang and Biren Amin.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use